Lebrikizumab - Roche

Drug Profile

Lebrikizumab - Roche

Alternative Names: MILR1444A; MILR1444Ab; RG-3637; RO-5490255; TNX-650

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Idiopathic pulmonary fibrosis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease

Most Recent Events

  • 14 Sep 2017 Dermira announces early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and closing of worldwide licensing transaction with Roche and Genentech, to develop and commercialsise lebrikizumab for Atopic dermatitis
  • 08 Aug 2017 Dermira enters into a worldwide licensing agreement with Roche and Genentech to develop and commercialise lebrikizumab in Atopic dermatitis
  • 08 Aug 2017 Dermira plans a dose-ranging phase IIb study to optimise the dose of lebrikizumab for the design of a phase III programme in moderate-to-severe Atopic dermatitis (In adults) in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top